Janus kinase inhibitors are a relatively novel class of drugs approved for IBD with the advantages of oral administration, rapid onset of action, quick clearance, and lack of immunogenicity.16 Furthermore, compared to biologics such as tumor necrosis factor (TNF) inhibitors or anti-α4β7 integrin inhibitors, which target a single molecule, JAK inhibitors exhibit a robust anti-inflammatory capability by simultaneously blocking multiple cytokines across various inflammatory pathways. This evidence concerns the gene TNF and inflammatory bowel disease.